Back to search results

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Metastatic Castration-resistant Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Tennessee Oncology PLLC, Nashville, Tennessee, United States

    Contact: Study coordinator (Caitlin J Pecknold) · cpecknold@tnonc.com
    Contact: Principal Investigator (Jeffery Russell)

  • START, San Antonio, Texas, United States

    Contact: Study coordinator (Edwin Blanco-Cepeda) · edwin.blancocepeda@startresearch.com · 210-593-5250
    Contact: Principal Investigator (Amita Patnaik)

  • Novartis Investigative Site, Olomouc, Czechia

  • Novartis Investigative Site, Odense C, Denmark

  • Novartis Investigative Site, Pierre-Bénite, France

  • Novartis Investigative Site, Jena, Thuringia, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Milan, Italy

  • Novartis Investigative Site, Kyoto, Japan

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Taipei, Taiwan

View source on ClinicalTrials.gov(opens in a new tab)